Michael Cohen Dallas Elder Lawyer |

29 Sep Donanemab – The Next New Drug Likely To Be Approved In Slowing Memory Decline

Posted at 11:17h in Alzheimer’s, Estate Planning, Medicaid Application, Medicaid Planning, Michael Cohen Dallas Elder Lawyer, Probate Administration, Quality of Life

Earlier this year, leqembi (a drug that slows memory decline for those in the early stages of Alzheimer’s Disease by targeting the amyloid protein, usually common with those inflicted with Alzheimer’s as it begins to form) was approved by both FDA and CMS (governmental assistance...

26 Jul FDA Grants Approval for Drug that Slows Memory Loss

Posted at 13:33h in Alzheimer’s, Dementia, End of Life Care Planning, Estate Planning, Medicaid Application, Medicaid Planning, Medicare, Michael Cohen Dallas Elder Lawyer, Probate Administration

A milestone event in the fight against Alzheimer’s Disease occurred on July 6 when the FDA gave approval for a drug (Leqembi) that not only slows memory loss for those with Alzheimer’s Disease, but it was granted funding approval by the Centers for Medicare &...

29 Sep SENATE SUBCOMMITTEE PROPOSED $350 MILLION INCREASE FOR ALZHEIMER’S AND DEMENTIA RESEARCH

Posted at 15:16h in Alzheimer’s, Dementia, End of Life Care Planning, Estate Planning

The Senate Labor-HHS Appropriations Subcommittee has proposed a $350 million increase, raising the total to $2.8 billion annually if passed into law, for research funding on Alzheimer’s and dementia for year 2020. The Senate Subcommittee saw the progress in dementia research being made by researchers...